Moderna undergoes clinical trials of mRNA-assisted flu vaccine

Moderna has introduced its flu-derived mRNA vaccine to a first-time volunteer as part of Phase 1/2 medical research, the company announced Wednesday.

This is a very early test of the new vaccine technology, especially for the first understanding of “safety, reactogenicity and immunogenicity,” according to Modern release. MRNA-1010, as the vaccine has been called, is designed to be effective against four of the most common strains of the virus, including H1N1, H3N2, influenza B, and B Victoria. According to the World Health Organization, these strains cause between 3 and 5 million flu cases each year, resulting in 650,000 tuberculosis deaths each year. In the US alone, about 8 percent of the population develops the flu each winter. The company expects the vaccine to be more effective than the 40 – 60% flu vaccine.

“We are pleased to have participated in this study of mRNA-1010, in our first phase of hospital admission. We hope that those who will get the flu vaccine due to the weather will be an important part of the vaccine in the future, “said Stéphane Bancel, CEO of Moderna. of mRNA includes the ability to combine different antigens to protect against multiple viruses and to quickly combat the mutations of respiratory viruses, such as influenza, SARS-CoV-2 and RSV. especially for respiratory viruses. “

The vaccine was made using the same methods that the company used make its COVID-19 support by 2020. This process works by using the human body’s cells to produce the virus that causes the DNA virus to help respond and protect the body against future infections. Since this method does not require any virus (either weak or dead) but only a summary of its genes, the mRNA vaccine can be used for any serious modern disease in combination malaria, tuberculosis – even cancer.